Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

The RAINBO program is a studies group which proposes personalized treatment of patients suffering from endometrial cancer according to their molecular profile. the RAINBO-RED study allows observation or maintenance treatment with targeted therapy for one year (olaparib). This after standard therapy. The goal is to improve recurrence-free survival of patients treated with Olaparib.

Trial Details

NCT ID
NCT06712472
Phase
PHASE3
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Olaparib (300 mg BID)
Locations (sample)
  • Albi, France|43.9298,2.148
  • Angers, France|47.47156,-0.55202
  • Besançon, France|47.24878,6.01815
  • Carcassonne, France|43.21649,2.34863
  • Dijon, France|47.31344,5.01391

Key Eligibility Criteria

  • Histologically confirmed diagnosis of EC (all grades and the following histologic subtypes : endometrioid, serous, clear cell, de-/undifferentiated…
  • Molecular classification performed following the diagnostic algorithm described in WHO 2020 (adapted from Vermij et al.)
  • TLH-BSO or TAH-BSO with or without lymphadenectomy or sentinel node biopsy, without macroscopic residual disease after surgery
  • No distant metastases as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or PET-CT scan)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →